{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T21:05:19.736160+00:00","company":{"ticker":"GMED","cik":1237831,"company_name":"GLOBUS MEDICAL INC"},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"808ccd924734e902ce5874ee4bb6bcb8a055449b","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-06-04T20:11:31+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval, on a non-binding, advisory basis, of the 2025 compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"6,902,949","subject":null,"votes_abstain":"71,589","votes_against":"5,212,943","votes_for":"316,289,675","votes_withheld":null}]},"claim":"GLOBUS MEDICAL INC shareholders approved Approval, on a non-binding, advisory basis, of the 2025 compensation of the Company’s named executive officers.","evidence_excerpt":"The Company’s stockholders approved, on a non-binding, advisory basis the 2025 compensation of the Company’s named executive officers, as described in the Proxy Statement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-040784","anchor_url":"https://secwatch.observer/filing/0001628280-26-040784#claim-808ccd924734e902ce5874ee4bb6bcb8a055449b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f1c879cba5f1be761dc6905fa103c98bdc820726","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-06-04T20:11:31+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-12-31","outcome":"passed","proposal_text":"Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"43,398","votes_against":"467,955","votes_for":"327,965,803","votes_withheld":null}]},"claim":"GLOBUS MEDICAL INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-12-31 meeting.","evidence_excerpt":"The Company’s stockholders approved the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-040784","anchor_url":"https://secwatch.observer/filing/0001628280-26-040784#claim-f1c879cba5f1be761dc6905fa103c98bdc820726","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm"},{"fact_type":"shareholder_vote","fact_key":"57adc7602b6f2ff8131be4f73dfdceae2907dc84","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-06-04T20:11:31+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of 2021 Equity Incentive Plan Amendment","proposal_type":"equity_plan","results":[{"broker_non_votes":"6,902,949","subject":null,"votes_abstain":"79,135","votes_against":"75,266,538","votes_for":"246,228,534","votes_withheld":null}]},"claim":"GLOBUS MEDICAL INC shareholders approved Approval of 2021 Equity Incentive Plan Amendment.","evidence_excerpt":"The Company’s stockholders approved the 2021 Equity Incentive Plan Amendment.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-040784","anchor_url":"https://secwatch.observer/filing/0001628280-26-040784#claim-57adc7602b6f2ff8131be4f73dfdceae2907dc84","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a0d8aa709d4cc5fd5f2d6edb116c83e7bf926bd4","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-06-04T20:11:31+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders","proposal_type":"director_election","results":[{"broker_non_votes":"6,902,949","subject":"Keith W. Pfeil","votes_abstain":null,"votes_against":null,"votes_for":"293,453,432","votes_withheld":"28,120,775"},{"broker_non_votes":"6,902,949","subject":"Robert A. Douglas","votes_abstain":null,"votes_against":null,"votes_for":"311,683,904","votes_withheld":"9,890,303"}]},"claim":"GLOBUS MEDICAL INC shareholders approved Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders.","evidence_excerpt":"Each of the director nominees listed below were elected by the Company’s stockholders at the Annual Meeting to serve a three-year term on the Board.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-040784","anchor_url":"https://secwatch.observer/filing/0001628280-26-040784#claim-a0d8aa709d4cc5fd5f2d6edb116c83e7bf926bd4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm"},{"fact_type":"earnings_release","fact_key":"9def495eb37802f000b12bdf6a13f6ddfc08f0bb","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$4.70 to $4.80","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2026","report_date":"2026-05-07","result_type":"guidance_update","revenue_text":"$3.18 billion to $3.22 billion"},"claim":"GLOBUS MEDICAL INC reported full-year 2026 results: revenue $3.18 billion to $3.22 billion, EPS $4.70 to $4.80. Guidance raised.","evidence_excerpt":"The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-032164","anchor_url":"https://secwatch.observer/filing/0001628280-26-032164#claim-9def495eb37802f000b12bdf6a13f6ddfc08f0bb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026032164/0001628280-26-032164-index.htm"},{"fact_type":"earnings_release","fact_key":"0dad7634d59c90b9b8966500bf6bf0bea3209ce6","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$0.90","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$124.3 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$759.9 million"},"claim":"GLOBUS MEDICAL INC reported the first quarter ended March 31, 2026 results: revenue $759.9 million, net income $124.3 million, EPS $0.90.","evidence_excerpt":"Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: • Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis. • Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis. • GAAP net income for the quarter was $124.3 million. • GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-032164","anchor_url":"https://secwatch.observer/filing/0001628280-26-032164#claim-0dad7634d59c90b9b8966500bf6bf0bea3209ce6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026032164/0001628280-26-032164-index.htm"},{"fact_type":"earnings_release","fact_key":"089a01d99577bf0137391810ad5aa4f27062ade9","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"($0.05)","guidance_signal":"unknown","item_codes_triggered":["2.02"],"net_income_text":"$7.1 million net loss","period_text":"three-month period ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$606.7 million"},"claim":"GLOBUS MEDICAL INC reported three-month period ended March 31, 2024 results: revenue $606.7 million, net income $7.1 million net loss, EPS ($0.05).","evidence_excerpt":"Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 3 1 , 202 4 .  · Worldwide net sales were $ 606.7 million , an increase of 119 . 3 % , or 119.8% on a constant currency basis · GAAP net loss for the quarter was $ 7. 1 million · GAAP d iluted e arnings p er share (“ EPS ”) was ( $0. 0","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001562762-24-000124","anchor_url":"https://secwatch.observer/filing/0001562762-24-000124#claim-089a01d99577bf0137391810ad5aa4f27062ade9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/0001562762-24-000124-index.htm"},{"fact_type":"earnings_release","fact_key":"da8cc65b443401edcb7187d2ec35d834e0127c9f","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-02-20T23:59:59+00:00","payload":{"eps_text":"$1.07","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$ 122.9 million","period_text":"the fiscal year ended December 31, 2023","report_date":"2024-02-20","result_type":"reported_results","revenue_text":"$ 1,568.5 million"},"claim":"GLOBUS MEDICAL INC reported the fiscal year ended December 31, 2023 results: revenue $ 1,568.5 million, net income $ 122.9 million, EPS $1.07. Guidance reaffirmed.","evidence_excerpt":"EPS ”) was $0. 11 and non-GAAP diluted EPS was $0. 60 · Non-GAAP adjusted EBITDA was $ 1 70.0 million, or 27. 6 % of net sales  Full Year 20 2 3 : · Worldwide net sales were $ 1,568.5 million , an increase of 53.3% on an actual and constant currency basis · GAAP n et income for the year was $ 122.9 million · GAAP d iluted EPS was $ 1.07 and n on-GAAP diluted EPS was $","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001562762-24-000030","anchor_url":"https://secwatch.observer/filing/0001562762-24-000030#claim-da8cc65b443401edcb7187d2ec35d834e0127c9f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000030/0001562762-24-000030-index.htm"},{"fact_type":"earnings_release","fact_key":"7126d0177759b7ff6e1d43814f412ad86057e177","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-02-20T23:59:59+00:00","payload":{"eps_text":"$0.11","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$ 15.0 million","period_text":"the fourth quarter ended December 31, 2023","report_date":"2024-02-20","result_type":"reported_results","revenue_text":"$ 616.5 million"},"claim":"GLOBUS MEDICAL INC reported the fourth quarter ended December 31, 2023 results: revenue $ 616.5 million, net income $ 15.0 million, EPS $0.11.","evidence_excerpt":"Worldwide net sales for the fourth quarter were $ 616.5 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001562762-24-000030","anchor_url":"https://secwatch.observer/filing/0001562762-24-000030#claim-7126d0177759b7ff6e1d43814f412ad86057e177","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000030/0001562762-24-000030-index.htm"},{"fact_type":"executive_change","fact_key":"45cd9fc48b","cik":1237831,"ticker":"GMED","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-02-05T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-02-01","interim":false,"role":"Chief Operating Officer and Chief Financial Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Keith Pfeil changed role as Chief Operating Officer and Chief Financial Officer at GLOBUS MEDICAL INC.","evidence_excerpt":"On February 5, 2024, Globus Medical, Inc. (the “Company”) issued a news release announcing the promotion of Keith Pfeil to Chief Operating Officer and Chief Financial Officer, effective as of February 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001562762-24-000019","anchor_url":"https://secwatch.observer/filing/0001562762-24-000019#claim-45cd9fc48b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000019/0001562762-24-000019-index.htm"}]}